Alva - Your AI Investing Agent

Oliver | MMMT Wealth

Founder of MMMT Wealth, CPA, Technical/Fundamental Analysis

8 Jul, 22:41Latest

AI's application layer remains the long-term bet: after 24 months in infrastructure on obvious earnings, capital must now move to the layer that produces durable economic value. Tempus AI's edge is proprietary data, which stays scarce as raw intelligence gets cheaper. Eli Lilly's LillyPod pairs 1,000 Blackwell GPUs with decades of clinical data, an underrated moat. Lemonade's tech yields cost, price and growth edges. Coinbase provides the stablecoin financial guardrails agentic AI needs. x.com

LLY

LMND

TEM

COIN

3 Jul, 11:31

Lemonade, Zeta and Palantir own the AI application layer, the most durable long-term edge as models commoditize, since infrastructure needs applications for data ownership, security, auditability and governance. Capital is not leaving the AI trade, only rotating out of hardware, with the equal-weight S&P 500 at record highs and hyperscaler capex guided above $700B for FY26. Palantir trades at about 1.1x PEG. Capex cuts, broad equity outflows or falling GPU rental prices would change the view. x.com x.com

LMND

ZETA

PLTR

Audit The Herd

CPA, Corporate Finance Professional

16 Aug

LMND

TEM

Lemonade and Tempus AI are where AI returns become visible, as capital moves from infrastructure up to the application layer. Big Tech's hundreds of billions in AI capex still show little attributable revenue and no clear moat beyond scale, and infrastructure depreciates. Lemonade's marketing buys customer relationships that can last decades and improve underwriting; Tempus's clinical dataset grows harder to replicate with each patient, backing pharma revenue with 126% NRR. x.com

Audit The Herd

CPA, Corporate Finance Professional

9 Oct

LMND

SITM

TEM

SiTime, Tempus AI and Lemonade look like AI beneficiaries that need not rely on rising frontier-model spending, unlike a crowded trade vulnerable to concentrated capital and circular financing. SiTime can expand into robotics even if data-center growth slows; clinical decisions still need Tempus; Lemonade's models may improve loss ratios and retention while lower compute costs could help it. x.com

Deep Sail Capital

Founder & CIO of Deep Sail Capital, Long/Short GARP, Quality/Growth/Micro-Caps

28 Sep

TEM

Tempus AI is a short idea because the stock is being pumped on recent FDA clearances for its EKG-AI tools, while the revenue from them is far off and may never materialize. x.com

Philip

Founder & CEO of Intrinsiqq, Value & Growth Investor

21 Oct

LLY

MDB

Most rivals cannot match these 12 stocks' moats. Micron is one of three HBM titans; Circle backs USDC; ASML alone makes EUV; Planet Labs has the largest Earth-imaging fleet. MongoDB is developers' choice; Affirm embeds at Amazon and Shopify; Eli Lilly leads GLP-1; SoFi spans loans, banking and investing. On gains via CloudTec; AST SpaceMobile builds phone satellites; Rigetti offers cloud quantum computing; Spotify, the largest music streamer, adds podcasts and audiobooks. x.com x.com x.com x.com … Show more

Rich Peter

Investor, Crypto, US Stocks & High-Dividend ETFs

16 Oct

LLY

Eli Lilly's GLP-1 and metabolic franchise can compound demand and cash flows while rate fears punish leveraged AI stories. It is preferable as a defensive-growth holding into its October 29 earnings over chasing a chip bounce. Continued healthcare volume leadership would support the sleeve; if semiconductors reclaim leadership first, the rotation is already crowded the other way. x.com x.com

FestivusCap

Public Equities Commentary

1 Oct

TEM

Tempus AI is a second- or third-tier genomic lab whose AI story is marketing mumbo jumbo, and its management team are promoters. x.com

Philip

Founder & CEO of Intrinsiqq, Value & Growth Investor

18 Oct

XYZ

AI, retail, healthcare and crypto exposure could make these 12 monster buys now. IREN builds AI cloud; Walmart grows ads and e-commerce; Netflix adds streaming ads; IonQ builds quantum computers and buys networking firms; Hims & Hers sells care direct; Coinbase earns from custody and stablecoins; Nvidia's CUDA locks in developers; Oscar targets self-insured customers; CoreWeave rents GPUs; Lumentum supplies AI optics; Block spans payments; Strategy holds bitcoin. x.com x.com x.com x.com x.com … Show more

Ashton Invests

Long-Term Equity Investor, Fundamental Stock Research

20 Oct

Better underwriting at Root, AI data demand at Innodata, defense breadth at Applied Aerospace & Defense, scaled voice AI at SoundHound, more organ access via TransMedics, profitable insurance at Lemonade, autonomous defense at Ondas and successful medicines at AbCellera could drive outsized growth. These eight smaller companies have a realistic path to 5x+ over 5-10 years if they execute on those opportunities. x.com x.com x.com x.com x.com x.com x.com x.com

VenkatP

Physician, Growth & Value Stock Investor

11 Jul

TEM

Tempus AI deserves a management-quality discount because of governance and credibility risk around Lefkofsky, not established medical malpractice. His history, including his Groupon tenure, how Tempus acquired Ambry, and unresolved allegations mean it should not be treated as a clean long-term compounder until cash flow, AI-derived revenue and related-party disclosures become much clearer. The stock may still trade well technically. x.com

Jordi Visser

Head of AI Macro Nexus Research at 22V

20 Oct

LLY

Eli Lilly can reinvest its GLP-1 cash flow into biological intelligence, building on the growth of its metabolic drugs. AI agent swarms working on scientific problems underpin the view that Lilly is becoming the world's most important AI company and could be the largest US company by decade's end. 2027 will be a year of cures and AI-driven scientific breakthroughs. x.com

Ask Alva about this thesis

Ask Alva about this thesis